It shows great potential in working synergistically with (1) paclitaxel in patients with advanced TNBC[102]; (2) radiotherapy in A-431 epidermoid carcinoma cells[103], and head and neck squamous cell carcinoma[104]; (3) Lutetium 177 (177Lu) DOTA-0-Tyr3-Octreotate (177Lu-DOTATATE) in neuroendocrine tumors[105]; (4) abiraterone acetate in prostate cancer[106]; (5) temozolomide against malignant gliomas[107]; (6) crizotinib or erlotinib in NSCLC[108]; (7) imatinib in patients with GIST[109]; (8) cisplatin in pancreatic cancer cells[110], and Bcl-2 inhibitor ABT-263 in breast cancer cells[111]. The gene discussed is BCL2; the disease is non-small cell lung carcinoma.